Our technology
Our proprietary therapeutic drug monitoring technology harnesses a powerful optics and photonics-based technique called Raman spectroscopy to identify and measure the structural fingerprints of molecules in complex biofluids like blood.
Each molecule or drug has a distinct combination of chemical bonds and bond types. Raman spectroscopy hits molecules with a powerful laser that interacts with these chemical bonds and the vibrations within the molecules, resulting in distinctive shifts in the energy of the laser photons.
The detection of this energy shift then provides the molecular fingerprints of therapeutic drugs, allowing us to rapidly and accurately quantify their concentration for clinical decision making.
Figure: Schematic diagram demonstrating our therapeutic drug monitoring system
Figure: Schematic diagram demonstrating our therapeutic drug monitoring system
Uncover the Active Drug Fraction
Other therapeutic drug monitoring techniques, like mass spectrometry and ELISA, typically measure the total amount of a drug present in a patient’s blood.
Our proprietary technology overcomes this issue as it measures only the free, pharmacologically active fraction of drugs.
This allows us to provide the most reliable results possible to drive accurate, tailored, and pharmacologically relevant dosing with no interference from background, even in complex biofluids like blood.
Figure: Only the active drug fraction is measured thanks to our proprietary technology
Unparalleled Adaptability
Our therapeutic drug monitoring technology requires no biomarker development, so it is easily transferable to other molecules and fields. This adaptability streamlines the detection of novel molecules without elaborate, time-consuming, and expensive research and development.
Save time and money with no compromise on quality.
An Ease-of-Use, Cost-Saving Therapeutic Drug Monitoring Revolution
Therapeutic drug monitoring at the point of need is a crucial step in the journey to a truly personalized healthcare landscape.
However, methods such as mass spectrometry and ELISA-based assays lack the necessary speed and ease of use for implementation at the bedside, where therapeutic drug monitoring would provide the most clinically actionable dosage guidance to drive better patient outcomes.
In contrast, our technology combines the sensitivity, specificity, and accuracy necessary for therapeutic drug monitoring to guide clinical dosage decisions and monitor drug adherence in clinical trials with rapid turnaround times, user-friendliness, and cost efficiency.
Figure: Comparison between mass spectrometry, immunoassays, and Axithra’s technology
Figure: Comparison between mass spectrometry, immunoassays, and Axithra’s technology
From Patient to Actionable Insights
Our lead application focuses on the therapeutic drug monitoring of β-lactam antibiotics in the intensive care unit.
Here’s how our point-of-need technology integrates seamlessly into the clinical workflow, from blood or plasma sample to actionable results.
